A pilot clinical trial assessing the efficacy and safety of supplementation with a B complex vitamin to reduce the incidence of chemotherapy induced peripheral neuropathy in patients diagnosed with a malignancy

Background: Chemotherapy-induced peripheral neuropathy [CIPN] is a common significant and debilitating side effect resulting from the administration of neurotoxic chemotherapeutic agents. These pharmaco–chemotherapeutics can include taxanes, vinca alkaloids, platinum analogues and others. Moderate to severe CIPN significantly decreases the quality of life and physical abilities of cancer patients and current pharmacotherapy for CIPN (e.g. Amifostine and antidepressants) have had limited efficacy and may themselves induce adverse side effects. Methods: To determine the potential use of herbal medicines as adjuvants in cancer treatments a critical literature review was conducted by electronic and manual search on nine databases. These include PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, Google Scholar and two Chinese databases CNKI and CINAHL. Thirty-four studies were selected from 5614 studies assessed and comprised of animal studies, case reports, retrospective studies and minimal randomized clinical trials investigating the anti-CIPN effect of herbal medicines as the adjuvant intervention in patients administered chemotherapy. The thirty-four studies were assessed on methodological quality and limitations identified. Results: Studies were mixed in their recommendations for herbal medicines as an adjuvant treatment for CIPN. Conclusion: Currently no agent has shown solid beneficial evidence to be recommended for the treatment or prophylaxis of CIPN. Given that the number of cancer survivors is increasing, the longterm side effects of cancer treatment, is of major importance.